ТОВАРИЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "IMEDICALPRO"
This is a company preview
Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.
Summary
Министерство юстиции РКActivities
1ОКЭДПроизводство готовых текстильных изделий, кроме одежды
Contacts
Change history
Financial statements
PremiumPublic contracts
Assets
Bank accounts
Leadership
1- ЖА
Жаншойнов Асхат Тлегенович
Director
since 13.05.2020
Founders
Accreditations
Employees
Affiliated companies
PremiumDirector's involvement in other legal entities
Branches
Risks
2/17Комитет государственных доходов · Государственные закупки РК · АО ФНБ «Самрук-Казына» · АОО «НИШ»This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.
Court cases
Arrests & encumbrances
Enforcement proceedings
Certificates
Licenses
Company networks
PremiumSimilar companies
Media mentions
Company summary
ТОО "IMEDICALPRO" (BIN 200540006523) is an active legal entity in Карагандинская область, registered in 2020 (6 years on the market). Primary activity — производство готовых текстильных изделий, кроме одежды. Per open government registries as of September 1, 2026: 2 government contracts on Портал государственных закупок РК (goszakup.gov.kz) worth 312,500 ₸. Automated screening found 2 risk indicators for "IMEDICALPRO". Director on record — Жаншойнов Асхат Тлегенович. Data current as of September 1, 2026.
Information is aggregated from open government registries of Kazakhstan: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is indexed automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the corresponding facts. This is reference information and does not replace an official extract. Learn more about the methodology and sources — SafeDeal editorial policy.